Astex Pharmaceuticals to Present at AACR-NCI-EORTC
14 oct. 2013 16h30 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced...
Astex Pharmaceuticals Responds to Further Misleading Claims Made by Sarissa Capital
09 oct. 2013 22h37 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), a pharmaceutical company dedicated to the discovery and development of novel small molecule...
Astex Pharmaceuticals Announces Expiration of HSR Waiting Period for Pending Transaction
07 oct. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that the waiting period for U.S. antitrust review under the Hart-Scott-Rodino...
Astex Pharmaceuticals Issues Open Letter to Stockholders Regarding Otsuka Transaction
02 oct. 2013 19h40 HE
|
Astex Pharmaceuticals, Inc.
Astex Board of Directors Corrects the Record Regarding Recent Mischaracterizations
Urges Stockholders to Tender Shares into Otsuka Offer
DUBLIN, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) -- The...
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 AML Data at the European Cancer Congress
30 sept. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Withdraws From Upcoming Investor Conferences
06 sept. 2013 18h45 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 6, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash
05 sept. 2013 03h48 HE
|
Astex Pharmaceuticals, Inc.
TOKYO and DUBLIN, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. ("Otsuka") and Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) ("Astex"), announced today that their respective...
Astex Pharmaceuticals to Present at Investor Conferences in September
03 sept. 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...
Astex Pharmaceuticals Announces Topline Results of SGI-110 AML Phase 2 Study
28 août 2013 06h00 HE
|
Astex Pharmaceuticals, Inc.
DUBLIN, Calif., Aug. 28, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX) today announced topline results from the ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase...
Astex Pharmaceuticals Reports 2013 Second Quarter Financial Results
01 août 2013 08h00 HE
|
Astex Pharmaceuticals, Inc.
SGI-110 Clinical Data Presented at EHA for Phase 1 MDS Patients
Second Quarter Royalty Revenue Increased 15% to $16.6 Million
Royalty Revenue Guidance Revised From $55 Million to $63 Million for...